or
Continue with FacebookLooking to list your PhD opportunities? Log in here.
This project is no longer listed on FindAPhD.com and may not be available.
Click here to search FindAPhD.com for PhD studentship opportunities
Dr Nial Wheate
Applications accepted all year round
Self-Funded PhD Students Only
About the Project
Platinum-based anticancer drugs are some of the most widely used agents in chemotherapy. Whilst they are effective, their use is limited by their severe side effects and the ability of cancers to develop resistance to further treatment. These problems can be overcome by designing better drugs and/or the development of novel delivery vehicles to better target the drugs only to tumour cells. Dr Wheate is an internationally renown scientist working at the forefront of platinum-based anticancer drugs. His research group undertakes a whole-of-pipeline approach to drug development which includes:
*Drug design and synthesis
*Understanding the mechanisms of drug action/DNA binding
*Preformulation and solid state polymorphism of drugs
*Application of drug delivery vehicles including macrocycles, polymers and nanoparticles.
*Active tumour targeting agents
*Dosage formulation
The Wheate group is currently seeking interested overseas students who wish to complete a PhD in platinum-based anticancer drugs.
Following this web address to see more details on the Wheate Group (http://sydney.edu.au/pharmacy/about/people/nial.shtml).
*Drug design and synthesis
*Understanding the mechanisms of drug action/DNA binding
*Preformulation and solid state polymorphism of drugs
*Application of drug delivery vehicles including macrocycles, polymers and nanoparticles.
*Active tumour targeting agents
*Dosage formulation
The Wheate group is currently seeking interested overseas students who wish to complete a PhD in platinum-based anticancer drugs.
Following this web address to see more details on the Wheate Group (http://sydney.edu.au/pharmacy/about/people/nial.shtml).
Funding Notes
Overseas applicants must have a scholarship from their government that covers stipends for the student, bench fees and tuition costs. Overseas applicants who are in the process of applying for a scholarship or have applied and are waiting for a decision may apply for a PhD position within the group
References
Recent examples of Wheate Group publications:
Gordon J. Kirkpatrick, Jane A. Plumb, Oliver B. Sutcliffe, David J. Flint and Nial J. Wheate, Evaluation of anionic half generation poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin, Journal of Inorganic Biochemistry, 2011, 105, 1115-1122.
Shonagh Walker, Rajdip Kaur, Fiona J. McInnes and Nial J. Wheate, Synthesis, processing and solid state excipient interactions of cucurbit[6]uril and its formulation into tablets for oral drug delivery, Molecular Pharmaceutics, 2010, 7, 2166-2172.
Sarah D. Brown, Paola Nativo, Jo-Ann Smith, David Stirling, Paul R. Edwards, Balaji Venugopal, David J. Flint, Jane A. Plumb, Duncan Graham and Nial J. Wheate, Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin, Journal of the American Chemical Society, 2010, 132, 4678-4684.
Anwen M. Krause-Heuer, Renate Grünert, Sybill Kühne, Magdalena Maruszak, Nial J. Wheate, Delphine Le Pevelen, Leanne R. Boag, Dianne M. Fisher, Jana Kasparkova, Jaroslav Malina, Patrick J. Bednarski, Viktor Brabec and Janice R. Aldrich-Wright, Studies into the mechanism of action of platinum(II) complexes with potent cytotoxicity in human cancer cells, Journal of Medicinal Chemistry, 2009, 52, 5474-5484.
Alan R. Kennedy, Alastair J. Florence, Fiona J. McInnes and Nial J. Wheate, A chemical preformulation study of a host-guest complex of cucurbit[7]uril and a multinuclear platinum agent for enhanced anticancer drug delivery, Dalton Transactions, 2009, 7695-7700.
Gordon J. Kirkpatrick, Jane A. Plumb, Oliver B. Sutcliffe, David J. Flint and Nial J. Wheate, Evaluation of anionic half generation poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin, Journal of Inorganic Biochemistry, 2011, 105, 1115-1122.
Shonagh Walker, Rajdip Kaur, Fiona J. McInnes and Nial J. Wheate, Synthesis, processing and solid state excipient interactions of cucurbit[6]uril and its formulation into tablets for oral drug delivery, Molecular Pharmaceutics, 2010, 7, 2166-2172.
Sarah D. Brown, Paola Nativo, Jo-Ann Smith, David Stirling, Paul R. Edwards, Balaji Venugopal, David J. Flint, Jane A. Plumb, Duncan Graham and Nial J. Wheate, Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin, Journal of the American Chemical Society, 2010, 132, 4678-4684.
Anwen M. Krause-Heuer, Renate Grünert, Sybill Kühne, Magdalena Maruszak, Nial J. Wheate, Delphine Le Pevelen, Leanne R. Boag, Dianne M. Fisher, Jana Kasparkova, Jaroslav Malina, Patrick J. Bednarski, Viktor Brabec and Janice R. Aldrich-Wright, Studies into the mechanism of action of platinum(II) complexes with potent cytotoxicity in human cancer cells, Journal of Medicinal Chemistry, 2009, 52, 5474-5484.
Alan R. Kennedy, Alastair J. Florence, Fiona J. McInnes and Nial J. Wheate, A chemical preformulation study of a host-guest complex of cucurbit[7]uril and a multinuclear platinum agent for enhanced anticancer drug delivery, Dalton Transactions, 2009, 7695-7700.
